Announcement • Feb 11
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office Q BioMed Inc. announced asset Uttroside B - is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA. In early pre-clinical investigation Q BioMed's Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs. Announcement • Oct 18
Q BioMed Inc. announced delayed 10-Q filing On 10/17/2022, Q BioMed Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Sep 28
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker Q BioMed Inc. announced receipt of a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 licensed from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness. However, with early detection and treatment, the eyes can be protected against serious vision loss. Currently, treatment for glaucoma is decided based on intraocular pressure (IOP) and perimetry. However, IOP has a huge variation from patient to patient and perimetry is a subjective test. Thus, a biomarker to aid in treatment decisions for glaucoma is needed. Currently, no single examination or diagnostic test is able to accurately predict disease progression. Accurate monitoring for disease progression is critical to preserve visual function in glaucoma patients, physicians only have surrogate measures to evaluate glaucomatous neurodegeneration. GDF15 represents an attractive biomarker for glaucoma with distinct advantages, including early detection, over conventional clinical tests and has the potential to be a first-in-class diagnostic test. GDF15 was discovered by Dr. Rajendra Apte, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences at Washington University School of Medicine.Q BioMed and its technology partner Mannin Research Inc. are currently developing therapeutics with novel mechanisms of action, to treat Primary Open-Angle Glaucoma. By offering both a diagnostic and a therapeutic, Q BioMed and Mannin are addressing the needs of both patients and physicians, as well as bringing innovation to the global glaucoma market estimated to affect over 100 million patients. Glaucoma is one of the leading causes of blindness worldwide. In 2017, researchers at Washington University School of Medicine in St. Louis identified the GDF15 biomarker, showing that it could predict damage to cells in the eye and be used to monitor severity and progression of glaucoma and facilitate treatment decisions and their effectiveness. Growth Differentiation Factor 15 is a member of the Transforming Growth Factor superfamily and was recently identified as a novel and promising biomarker for glaucoma, and its expression correlated with disease severity and progression. GDF15 has been validated in human patients with glaucoma. Beyond reduction of intraocular pressure, the desired goal of any glaucoma therapeutic is neuroprotection, or to be more specific, protection and survival of retinal ganglion cells. 
